Sign Out
Orlistat is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater than or equal to 30 kg/m2, or overweight patients (BMI ≥28 kg/m2) with associated risk factors. Treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight as measured at the start of therapy.
Adolescents: Obese adolescents should be treated with orlistat only if measures carried out in a therapeutic program over 6 months, including a balanced diet appropriate to the age of the patient and a program of physical activity are not successful.
